Literature DB >> 9252006

Effects of the combined oral administration of NSAIDs and dextromethorphan on behavioral symptoms indicative of arthritic pain in rats.

D D Price1, J Mao, J Lu, F S Caruso, H Frenk, D J Mayer.   

Abstract

The effects of combined single oral treatments with non-steroidal anti-inflammatory drugs (NSAIDs) and the non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist dextromethorphan (DM) on arthritic pain were examined in a rat model of adjuvant-induced arthritis. Although 12.5-100 mg/kg doses of DM alone produced no reliable effects, treatments with ibuprofen (IB, 50 and 100 mg/kg but not 12.5 or 25 mg/kg) produced mild analgesia in arthritic rats as determined using the Randall-Sellito test. IB showed a dose-response relationship which appeared to plateau at doses of 50 and 100 mg/kg. Adding 50 mg/kg DM to each IB dose resulted in significantly greater analgesic activity than IB alone at doses of 25, 50 and 100 mg/kg. A similar interaction between 50 mg/kg DM and 50 mg/kg IB occurred with respect to spontaneous pain behavior. Adding 25 mg/kg DM to 25 mg/kg IB likewise increased analgesia as measured by both the Randall-Sellito and spontaneous pain behavior tests (both P < 0.05). Five more NSAIDs were evaluated using the Randall-Sellito test, which included naproxen (NP), piroxicam (PIR), etodolac (ET), diclofenac (DC), and ketorolac (KE). For all six NSAIDS, the addition of 50 mg/kg DM reliably increased their analgesic potency, as indicated by reliable increases in previously effective NSAID doses (all six NSAIDs) as well as previously ineffective NSAID doses (IB, NP, DC, and PIR). These data demonstrate that DM greatly potentiates the analgesic activity of IB, DC, NP, PIR, ET, and KT and increases the peak effect over the NSAIDs alone. Similiar to DM's previously demonstrated enhancement of opioid analgesia in acute pain, the combination of DM and an NSAID may represent a novel analgesic approach to improved management of arthritic pain.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9252006

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  7 in total

Review 1.  Glutamate receptors and nociception: implications for the drug treatment of pain.

Authors:  M E Fundytus
Journal:  CNS Drugs       Date:  2001-01       Impact factor: 5.749

2.  Impairments in water maze learning of aged rats that received dextromethorphan repeatedly during adolescent period.

Authors:  Tie Yuan Zhang; Hee Jeong Cho; Seoul Lee; Jong-Ho Lee; Si Ho Choi; Vitaly Ryu; Sang Bae Yoo; Joo Young Lee; Dong Goo Kim; Jeong Won Jahng
Journal:  Psychopharmacology (Berl)       Date:  2006-10-05       Impact factor: 4.530

Review 3.  New dosage formulations for targeted delivery of cyclo-oxygenase-2 inhibitors: focus on use in the elderly.

Authors:  Shyam S Bansal; Abhijeet Joshi; Arvind K Bansal
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

4.  Synergistic depression of NMDA receptor-mediated transmission by ketamine, ketoprofen and L-NAME combinations in neonatal rat spinal cords in vitro.

Authors:  I Lizarraga; J P Chambers; C B Johnson
Journal:  Br J Pharmacol       Date:  2007-12-17       Impact factor: 8.739

5.  Comparison of effect of intravenous ketamine, peritonsillar infiltration of tramadol and their combination on pediatric posttonsillectomy pain: A double-blinded randomized placebo-controlled clinical trial.

Authors:  A Honarmand; M Safavi; P Kashefi; B Hosseini; S Badiei
Journal:  Res Pharm Sci       Date:  2013-07

6.  Ovariectomy ameliorates dextromethorphan--induced memory impairment in young female rats.

Authors:  Jeong Won Jahng; Hee Jeong Cho; Jae Goo Kim; Nam Youl Kim; Seoul Lee; Yil Seob Lee
Journal:  J Cell Mol Med       Date:  2006 Jan-Mar       Impact factor: 5.310

7.  Topical Anti-Inflammatory and Analgesic Activities of Citrullus colocynthis Extract Cream in Rats.

Authors:  Marzieh Pashmforosh; Hossein Rajabi Vardanjani; Hassan Rajabi Vardanjani; Mahdi Pashmforosh; Mohammad Javad Khodayar
Journal:  Medicina (Kaunas)       Date:  2018-07-29       Impact factor: 2.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.